Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does GLICLAZIDE Cause Contraindicated product administered? 88 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 88 reports of Contraindicated product administered have been filed in association with GLICLAZIDE. This represents 1.5% of all adverse event reports for GLICLAZIDE.

88
Reports of Contraindicated product administered with GLICLAZIDE
1.5%
of all GLICLAZIDE reports
3
Deaths
49
Hospitalizations

How Dangerous Is Contraindicated product administered From GLICLAZIDE?

Of the 88 reports, 3 (3.4%) resulted in death, 49 (55.7%) required hospitalization, and 2 (2.3%) were considered life-threatening.

Is Contraindicated product administered Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for GLICLAZIDE. However, 88 reports have been filed with the FAERS database.

What Other Side Effects Does GLICLAZIDE Cause?

Hypoglycaemia (756) Nausea (596) Acute kidney injury (553) Drug ineffective (507) Fall (415) Dyspnoea (400) Vomiting (385) Lactic acidosis (373) Malaise (360) Hypertension (351)

What Other Drugs Cause Contraindicated product administered?

ABATACEPT (13,559) METHOTREXATE (13,121) ETANERCEPT (12,062) TOCILIZUMAB (11,547) ADALIMUMAB (11,270) LEFLUNOMIDE (11,206) HYDROXYCHLOROQUINE (10,557) RITUXIMAB (10,479) INFLIXIMAB (9,618) SULFASALAZINE (8,698)

Which GLICLAZIDE Alternatives Have Lower Contraindicated product administered Risk?

GLICLAZIDE vs GLIMEPIRIDE GLICLAZIDE vs GLIMEPIRIDE\ROSIGLITAZONE GLICLAZIDE vs GLIPIZIDE GLICLAZIDE vs GLIVEC GLICLAZIDE vs GLOFITAMAB

Related Pages

GLICLAZIDE Full Profile All Contraindicated product administered Reports All Drugs Causing Contraindicated product administered GLICLAZIDE Demographics